28087508|t|International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial
28087508|a|Regional differences in risk of diabetes mellitus and cardiovascular outcomes in people with impaired glucose tolerance are poorly characterized. Our objective was to evaluate regional variation in risk of new-onset diabetes mellitus, cardiovascular outcomes, and treatment effects in participants from the NAVIGATOR (Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research) trial. NAVIGATOR randomized people with impaired glucose tolerance and cardiovascular risk factors or with established cardiovascular disease to valsartan (or placebo) and to nateglinide (or placebo) with a median 5-year follow-up. Data from the 9306 participants were categorized by 5 regions: Asia (n=552); Europe (n=4909); Latin America (n=1406); North America (n=2146); and Australia, New Zealand, and South Africa (n=293). Analyzed outcomes included new-onset diabetes mellitus; cardiovascular death; a composite cardiovascular outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke; and treatment effects of valsartan and nateglinide. Respective unadjusted 5-year risks for new-onset diabetes mellitus, cardiovascular death, and the composite cardiovascular outcome were 33%, 0.4%, and 4% for Asia; 34%, 2%, and 6% for Europe; 37%, 4%, and 8% for Latin America; 38%, 2%, and 6% for North America; and 32%, 4%, and 8% for Australia, New Zealand, and South Africa. After adjustment, compared with North America, European participants had a lower risk of new-onset diabetes mellitus (hazard ratio 0.86, 95% CI 0.78-0.94; P=0.001), whereas Latin American participants had a higher risk of cardiovascular death (hazard ratio 2.68, 95% CI 1.82-3.96; P<0.0001) and the composite cardiovascular outcome (hazard ratio 1.48, 95% CI 1.15-1.92; P=0.003). No differential interactions between treatment and geographic location were identified. Major regional differences regarding the risk of new-onset diabetes mellitus and cardiovascular outcomes in NAVIGATOR participants were identified. These differences should be taken into account when planning global trials. URL: http://www.ClinicalTrials.gov. Unique identifier: NCT00097786.
28087508	0	13	International	T078	C1512888
28087508	14	23	Variation	T080	C0205419
28087508	27	35	Outcomes	T062	C0086750
28087508	36	48	Among People	T033	C0517295
28087508	54	76	Cardiovascular Disease	T047	C0007222
28087508	80	107	Cardiovascular Risk Factors	T047	C0850624
28087508	112	138	Impaired Glucose Tolerance	T047	C0271650
28087508	140	148	Insights	T041	C0233820
28087508	158	173	NAVIGATOR Trial	T034	C0159069
28087508	174	194	Regional differences	T033	C0682132
28087508	198	223	risk of diabetes mellitus	T033	C0580321
28087508	228	242	cardiovascular	T029	C3887460
28087508	243	251	outcomes	T062	C0086750
28087508	255	261	people	T098	C0027361
28087508	267	293	impaired glucose tolerance	T047	C0271650
28087508	298	318	poorly characterized	T080	C0205617
28087508	350	358	regional	T082	C0205147
28087508	359	368	variation	T080	C0205419
28087508	372	376	risk	T078	C0035647
28087508	380	407	new-onset diabetes mellitus	UnknownType	C0743128
28087508	409	423	cardiovascular	T029	C3887460
28087508	424	432	outcomes	T062	C0086750
28087508	438	455	treatment effects	T033	C1518681
28087508	459	471	participants	T098	C0679646
28087508	481	490	NAVIGATOR	T034	C0159069
28087508	492	503	Nateglinide	T116,T121	C0903898
28087508	508	517	Valsartan	T109,T121	C0216784
28087508	521	547	Impaired Glucose Tolerance	T047	C0271650
28087508	548	565	Outcomes Research	T062	C0086750
28087508	567	572	trial	T034	C0159069
28087508	574	583	NAVIGATOR	T034	C0159069
28087508	584	594	randomized	T062	C0034656
28087508	595	601	people	T098	C0027361
28087508	607	633	impaired glucose tolerance	T047	C0271650
28087508	638	665	cardiovascular risk factors	T047	C0850624
28087508	674	685	established	T080	C0443211
28087508	686	708	cardiovascular disease	T047	C0007222
28087508	712	721	valsartan	T109,T121	C0216784
28087508	726	733	placebo	T122	C1696465
28087508	742	753	nateglinide	T116,T121	C0903898
28087508	758	765	placebo	T122	C1696465
28087508	774	780	median	T082	C2939193
28087508	788	797	follow-up	T058	C1522577
28087508	799	803	Data	T078	C1511726
28087508	818	830	participants	T098	C0679646
28087508	853	860	regions	T083	C0017446
28087508	862	866	Asia	T083	C0003980
28087508	876	882	Europe	T083	C0015176
28087508	893	906	Latin America	T083	C0023122
28087508	917	930	North America	T083	C0028405
28087508	945	954	Australia	T083	C0004340
28087508	956	967	New Zealand	T083	C0027978
28087508	973	985	South Africa	T083	C0037712
28087508	1004	1012	outcomes	T062	C0086750
28087508	1022	1049	new-onset diabetes mellitus	UnknownType	C0743128
28087508	1051	1065	cardiovascular	T029	C3887460
28087508	1066	1071	death	T033	C1306577
28087508	1075	1084	composite	T080	C0205199
28087508	1085	1099	cardiovascular	T029	C3887460
28087508	1100	1107	outcome	T062	C0086750
28087508	1111	1125	cardiovascular	T029	C3887460
28087508	1126	1131	death	T033	C1306577
28087508	1142	1163	myocardial infarction	T047	C0027051
28087508	1177	1183	stroke	T047	C0038454
28087508	1189	1206	treatment effects	T033	C1518681
28087508	1210	1219	valsartan	T109,T121	C0216784
28087508	1224	1235	nateglinide	T116,T121	C0903898
28087508	1248	1258	unadjusted	T169	C1439367
28087508	1266	1271	risks	T078	C0035647
28087508	1276	1303	new-onset diabetes mellitus	UnknownType	C0743128
28087508	1305	1319	cardiovascular	T029	C3887460
28087508	1320	1325	death	T033	C1306577
28087508	1335	1344	composite	T080	C0205199
28087508	1345	1359	cardiovascular	T029	C3887460
28087508	1360	1367	outcome	T062	C0086750
28087508	1395	1399	Asia	T083	C0003980
28087508	1421	1427	Europe	T083	C0015176
28087508	1449	1462	Latin America	T083	C0023122
28087508	1484	1497	North America	T083	C0028405
28087508	1523	1532	Australia	T083	C0004340
28087508	1534	1545	New Zealand	T083	C0027978
28087508	1551	1563	South Africa	T083	C0037712
28087508	1597	1610	North America	T083	C0028405
28087508	1612	1620	European	T098	C0239307
28087508	1621	1633	participants	T098	C0679646
28087508	1640	1650	lower risk	T081	C3538919
28087508	1654	1681	new-onset diabetes mellitus	UnknownType	C0743128
28087508	1683	1695	hazard ratio	T081	C2985465
28087508	1706	1708	CI	T081	C0009667
28087508	1738	1752	Latin American	T098	C1553378
28087508	1753	1765	participants	T098	C0679646
28087508	1779	1783	risk	T078	C0035647
28087508	1787	1801	cardiovascular	T029	C3887460
28087508	1802	1807	death	T033	C1306577
28087508	1809	1821	hazard ratio	T081	C2985465
28087508	1832	1834	CI	T081	C0009667
28087508	1874	1888	cardiovascular	T029	C3887460
28087508	1889	1896	outcome	T062	C0086750
28087508	1898	1910	hazard ratio	T081	C2985465
28087508	1921	1923	CI	T081	C0009667
28087508	1945	1960	No differential	T033	C3842396
28087508	1974	1981	between	T082	C0205103
28087508	1982	1991	treatment	T169	C0039798
28087508	1996	2015	geographic location	T083	C0017446
28087508	2039	2059	regional differences	T033	C0682132
28087508	2082	2109	new-onset diabetes mellitus	UnknownType	C0743128
28087508	2114	2128	cardiovascular	T029	C3887460
28087508	2129	2137	outcomes	T062	C0086750
28087508	2141	2150	NAVIGATOR	T034	C0159069
28087508	2151	2163	participants	T098	C0679646
28087508	2151	2163	participants	T098	C0679646
28087508	2169	2179	identified	T080	C0205396
28087508	2187	2198	differences	T080	C1705242
28087508	2242	2248	global	T080	C2348867
28087508	2249	2255	trials	T062	C0008976